{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:10:10Z","timestamp":1790727010288,"version":"4.1.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Pheochromocytomatosis refers to pheochromocytoma tumorlets developed as a result of seeding of tumor cells around the surgical bed due to intraoperative tumor capsule rupture and tumor cell spillage. As pheochromocytomatosis is relatively rare, optimal management is not clear. We describe a 42-year-old man with progressive pheochromocytomatosis despite surgical debulking. He did not have a family history of pheochromocytoma or harbor mutations in pheochromocytoma-predisposing genes. The pheochromocytomatosis tumorlets exhibited uptake on DOTATATE PET. He underwent PRRT (peptide receptor radionuclide therapy), which stabilized the pheochromocytomatosis progression. This case highlights the rare phenomenon of pheochromocytomatosis and the utility of PRRT in treating it.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003973","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T18:04:11Z","timestamp":1642010651000},"page":"e276-e278","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Pheochromocytomatosis Treated With Peptide Receptor Radionuclide Therapy"],"prefix":"10.1097","volume":"47","author":[{"given":"Martin S.","family":"Auerbach","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Department of Molecular and Medical Pharmacology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masha J.","family":"Livhits","sequence":"additional","affiliation":[{"name":"Section of Endocrine Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, UCLA David Geffen School of Medicine, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1067\/msy.2001.118373","article-title":"Iatrogenic pheochromocytomatosis: a previously unreported result of laparoscopic adrenalectomy","volume":"130","year":"2001","journal-title":"Surgery"},{"key":"bib2-20250621","first-page":"17-0026","article-title":"Pheochromocytomatosis associated with a novel TMEM127 mutation","volume":"2017","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"bib3-20250621","first-page":"345","article-title":"Pheochromocytomatosis after adrenalectomy: metastasis or cell seeding?","volume":"91","year":"2020","journal-title":"Chirurg"},{"key":"bib4-20250621","first-page":"dgz074","article-title":"Long-term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG","volume":"105","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-specific-activity-131I-MIBG versus 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma","volume":"27","year":"2021","journal-title":"Clin Cancer Res"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"625312","DOI":"10.3389\/fendo.2021.625312","article-title":"Somatostatin receptors and analogs in pheochromocytoma and paraganglioma: old players in a new precision medicine world","volume":"12","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:06:55Z","timestamp":1750536415000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003973","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,12]]}}}